Status:
WITHDRAWN
Tranexamic Acid Study
Lead Sponsor:
Texas Tech University Health Sciences Center
Conditions:
Arthroplasty, Replacement, Hip
Eligibility:
All Genders
18-100 years
Phase:
NA
Brief Summary
The purpose of this study is to determine if tranexamic acid significantly reduces blood loss and blood transfusion in revision total hip replacement. Tranexamic acid is a drug that helps to reduce bl...
Detailed Description
Tranexamic acid is an anti-fibrinolytic agent that inhibits fibrinolysis leading to a reduction of blood loss without concurrently increasing the risk of thromboembolic complications. Several studies ...
Eligibility Criteria
Inclusion
- Failed primary total hip arthroplasty (femoral stem, acetabular component, or both)
- 18-100 years of age
Exclusion
- Prosthetic infection
- Primary total hip arthroplasty
- Prisoners
- Pregnancy
- Previous adverse reaction to tranexamic acid
- Bleeding/coagulation disorders
- Renal insufficiency (serum creatinine\>two standard deviations for age)
- History of deep venous thrombosis or pulmonary embolism
- Religious beliefs/practices prohibiting blood transfusions
- Wards of the state
- Cognitively impaired patients
- Terminally ill patients
- Students and/or employees
- Color blindness
Key Trial Info
Start Date :
February 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2008
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00375440
Start Date
February 1 2005
End Date
January 1 2008
Last Update
October 5 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Texas Tech University Health Sciences Center Department of Orthopaedic Surgery
Lubbock, Texas, United States, 79430